Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2009 June;55(2) > Minerva Gastroenterologica e Dietologica 2009 June;55(2):123-38

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GASTROENTEROLOGICA E DIETOLOGICA

A Journal on Gastroenterology, Nutrition and Dietetics


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  


Minerva Gastroenterologica e Dietologica 2009 June;55(2):123-38

language: English

Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma

Hussain K. 1, El-Serag H. B. 2

1 Sections of Gastroenterology and Health Services Research Michael E. DeBakey Veterans Affairs Medical Center
and Baylor College of Medicine, Houston, TX, USA
2 College of Pharmacy University of Houston, Houston, TX, USA


PDF  


Globally, over half a million people develop hepatocellular carcinoma (HCC) each year and an almost equal number die of it. Some aspects of HCC remain disappointingly unchanged. For example, hepatitis B infection, for which an effective safe vaccine has been developed, remains responsible for a substantial proportion of cases worldwide. Further, the overall survival of patients with HCC remains very low. Nevertheless, the past few years have witnessed several important advances in our understanding of risk factors, screening, as well as treatment of HCC; these advances may change some of the current realities for HCC. In this paper, we will review the epidemiology, screening, diagnosis, and treatment of HCC with special emphasis on recent developments such the role of fatty liver disease, obesity, and coffee may play in causing HCC, the recent guidelines in screening and diagnosis, and state-of-the-art treatment algorithms.

top of page

Publication History

Cite this article as

Corresponding author e-mail